Probiotics are widely used as an adjuvant therapy in various diseases. Nonetheless, it is uncertain how they affect the gut microbiota composition and metabolic and inflammatory outcomes in women who have recently experienced gestational diabetes mellitus (post-GDM). A randomized, double-blind, placebo-controlled clinical trial involving 132 asymptomatic post-GDM women was conducted to close this gap (Clinical Trial Registration: NCT05273073). The intervention (probiotics) group received a cocktail of six probiotic strains from Bifidobacterium and Lactobacillus for 12 weeks, while the placebo group received an identical sachet devoid of living microorganisms. Anthropometric measurements, biochemical analyses, and 16S rRNA gene sequencing results were evaluated pre- and post-intervention. After the 12-week intervention, the probiotics group’s fasting blood glucose level significantly decreased (mean difference −0.20 mmol/L; p = 0.0021). The HbA1c, total cholesterol, triglycerides, and high-sensitivity C-reactive protein levels were significantly different between the two groups (p < 0.05). Sequencing data also demonstrated a large rise in the Bifidobacterium adolescentis following probiotic supplementation. Our findings suggest that multi-strain probiotics are beneficial for improved metabolic and inflammatory outcomes in post-GDM women by modulating gut dysbiosis. This study emphasizes the necessity for a comprehensive strategy for postpartum treatment that includes probiotics to protect post-GDM women from developing glucose intolerance.
Background: Early-life gut microbiota plays a fundamental role in immune and metabolic development. Although probiotics have been widely investigated in paediatric populations, evidence regarding microbial cell preparation (MCP)-associated probiotic formulations, in which selected probiotic strains are incorporated into a standardized microbial preparation, remains fragmented. Objectives: This narrative review synthesizes current evidence on the potential role of MCP-associated strains in supporting gut health, immune modulation, and clinical outcomes in infants and children. Methods: A narrative literature review was conducted comprising peer-reviewed articles identified from major scientific databases. Grey literature, including unpublished conference presentations and institutional research materials, was also included. Studies were selected based on their relevance to the functional properties and clinical applications in paediatric populations. Results: Available evidence suggests that MCP-associated strains, including Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium infantis, contribute to improve gut barrier function, enrich healthy microbial composition, and modulate immune homeostasis through the production of short-chain fatty acids (SCFAs), bacteriocins, and exopolysaccharides. Clinical evidence has suggested potential benefits in growth outcomes among small-for-gestational-age (SGA) infants, reduction in the duration of certain infectious episodes, and prevention of selected neonatal and paediatric infections, with a favourable safety and tolerability profile. Conclusions: MCP-associated probiotic interventions may have potential roles as adjunctive therapies in paediatric care, supporting gut and immune health and contributing to the growing body of evidence in this field. Further multidisciplinary research is required to establish standardized protocols and strengthen the evidence base for microbiome-targeted therapeutics in children.
Polypropylene (PP) is widely used, but its fragmentation into microplastics raises concerns about environmental accumulation and potential human exposure through ingestion and medical settings. These microplastics may disrupt microbiota composition and intestinal functions, highlighting the need to explore microbial interactions and biodegradation potential. Although probiotics are increasingly recognized for their benefits to gut health, their potential to degrade microplastics, particularly PP, remains largely unexplored. To address this gap, the present study evaluates the ability of Bifidobacterium bifidum BCMC® 12130, Bifidobacterium longum BCMC® 02120, and Bifidobacterium longum subsp. infantis BCMC® 02129 to biodegrade PP powder and commercially available PP film under controlled laboratory conditions. Preliminary concentration screening with Bifidobacterium longum BCMC® 02120 showed the greatest apparent bacterial growth response at 0.10% (w/v) PP. For the subsequent 30-day exposure experiment, however, PP was standardized at 0.01% (w/v). Following incubation at 25 ± 2 °C with agitation, changes in recovered PP mass and surface morphology were assessed. Among the strains tested, B. longum BCMC® 02120 exhibited the greatest reduction in recovered PP powder mass, with an 86.7% decrease after 30 days (p < 0.05). Scanning electron microscopy revealed dense biofilm formation alongside surface roughening, voids, and erosion, consistent with microbial colonization and deterioration of the polymer surface. Energy-dispersive X-ray spectroscopy showed a decrease in surface carbon content from 92.62% to 90.00% and from 7.38% to 10.00%, respectively; however, these changes were not statistically significant. Together, these preliminary findings suggest that the probiotic strain B. longum BCMC® 02120 has potential for PP microplastic biodegradation. Further studies are needed to confirm polymer breakdown and determine whether this activity could help mitigate microplastic-related effects on gut health.
Polypropylene (PP) is a widely used plastic that can fragment into microplastics, raising concerns about environmental accumulation and human health, particularly through ingestion and medical exposure. These microplastics may disrupt microbiota and intestinal function, highlighting the need to explore microbial interactions and biodegradation potential. Although probiotics are increasingly recognised for their benefits to gut health, their potential to degrade microplastics, particularly PP, remains largely unexplored. To address this gap, the present study evaluates the ability of Bifidobacterium bifidum BCMC® 12130, Bifidobacterium longum BCMC® 02120, and Bifidobacterium longum subsp. infantis BCMC® 02129 to biodegrade PP powder and commercially available PP film under controlled laboratory conditions. Bacterial growth was screened in Bushnell-Haas broth (BHB) containing varying PP concentrations, followed by incubation at 25℃ with agitation. The results identified 0.10% (w/v) PP as the optimal concentration, and B. longum BCMC® 02120 demonstrated significant degradation, achieving an 86.7% reduction in PP mass after 30 days (P < 0.05). Scanning electron microscopy revealed dense biofilm formation alongside surface roughening, voids, and erosion, consistent with microbial colonisation and deterioration of the polymer surface. Energy-dispersive X-ray spectroscopy showed a decrease in surface carbon content from 92.62% to 90.00% and an increase in oxygen content from 7.38% to 10.00%, suggesting possible surface oxidation. Together, these preliminary findings suggest that the probiotic strain B. longum BCMC® 02120 has potential for PP microplastic biodegradation. Further studies are needed to confirm polymer breakdown and determine whether this activity could help mitigate microplastic-related effects on gut health.